Yidu Tech 02158.HK just crossed a profitability threshold that matters far beyond one stock. With its first full-year net profit and accelerating cash discipline, the Beijing-based AI healthcare player is showing how China’s policy-led innovation and data scale convert into investable returns. The result is another proof point that China’s AI stack is moving from lab demos to durable, repeatable profits across critical industries.
For the fiscal year ended March 31, 2026, Yidu Tech posted its first full-year net profit of RMB 78.8 million, beating prior guidance and delivering RMB 72.7 million attributable to owners, roughly 30 percent above the upper end of guided range. Revenue rose 14.6 percent to RMB 820 million, while adjusted EBITDA surged more than 4.6 times to RMB 220 million. Gross margin expanded to 36.4 percent from 33.5 percent, and net operating cash flow turned positive in the second half at RMB 29.3 million. Management framed the inflection as structural, not opportunistic. “The first full-year profit was not driven by one-off factors,” said Executive Director and CFO Feng Xiaoying, citing mix optimization, higher margins, and operating leverage. That disciplined tone is what institutions want to hear from AI platforms transitioning into commercial scale and should dampen concerns that profit is a transient artifact of project timing.
The technology engine behind the print is YiduCore, a healthcare-specific AI infrastructure trained on real clinical pathways and outcomes. This is not about a single large model. It is an integrated stack joining data governance, medical knowledge graphs, disease models, healthcare LLMs, and workflow integrations. As of March 31, 2026, YiduCore had processed nearly 9 billion authorized real-world medical records, underpinned by standardized governance and compliant authorization. Its proprietary disease repository spans more than 100 areas and supports 21 disease-specific datasets. That density of labeled, longitudinal health data is hard to replicate and compounds with use. The CEO, Xu Jiming, called FY2026 a pivot from “long-term capability building to commercial value realization,” with an explicit strategy to standardize hospital products and push AI from bespoke delivery into scalable platforms.
The cornerstone AI for Medical segment delivered RMB 380 million in revenue, up 10.2 percent year over year, anchored by 133 leading hospitals and 54 regulatory and policymaking bodies. The company’s hospital network now covers more than 12,000 medical institutions nationwide. New orders point to pipeline depth: AI for Medical bookings rose 22.3 percent, while AI for Life Sciences rose 42.0 percent. That includes multi-million renminbi provincial builds such as Hainan’s Regional Infectious Disease Surveillance, Early Warning and Emergency Command Information Platform and the Hainan Smart Health Island initiative, each valued above RMB 10 million. Yidu also played an active role in National AI Application Pilot Bases in Beijing and Henan, putting the company at the intersection of policy and procurement. This mix across providers, regulators, pharma, and insurers reduces cyclicality and sets up a smoother revenue cadence as platform products displace custom projects.
Investors tracking China’s innovation cycle can see the pattern. Policy creates demand, domestic scale creates data, and platform companies convert that scale into exportable products. It has already played out in EVs and batteries, where Chinese brands control two-thirds of global EV sales and China supplies roughly 70 percent of the world’s batteries. It is visible in robotics, where a national initiative targets more than 10,000 humanoid robots in commercial use by end-2026 and Unitree Robotics moved its IPO application forward in June. And it is visible in energy storage, where Chinese firms signed over 127 GWh of projects this year. Healthcare AI is the next flywheel. Clinical-grade models demand large, clean, authorized data and the ability to embed into workflows at scale. Yidu’s nine-billion-record corpus, disease models, and regulatory projects signal that China’s AI stack is not just generalized dialog systems; it is domain-specific, safety-led, and manufacturable at platform economics. That is precisely what will travel to emerging markets hungry for hospital digitization and payer analytics.
1) Beating guidance with margin expansion: net profit RMB 78.8m, GM 36.4 percent; 2) EBITDA scale: RMB 220m adjusted EBITDA, up more than 4.6x; 3) Cash discipline: positive operating cash flow in H2 at RMB 29.3m; 4) Bookings health: new orders up 22.3 percent in Medical and 42.0 percent in Life Sciences; 5) Platform reuse: YiduCore serving hospitals, regulators, pharma, and insurers; 6) Policy alignment: roles in National AI Application Pilot Bases in Beijing and Henan; 7) Project-to-product shift: hospital solutions moving toward standardization and productization. Ticker: 02158.HK.
For investors benchmarking AI healthcare names in Hong Kong and mainland China, the key is operating leverage from standardized product lines atop proprietary data moats. Yidu’s improved gross margin and H2 cash inflection indicate licensing and platform revenue outweighing lower-margin custom builds. With RMB 380 million from AI for Medical and an expanding life sciences book, the earnings mix skews toward repeatable contracts, including regulatory platforms that often anchor multi-year budgets. In a market that has rewarded scale moats in EVs and batteries, expect investors to price healthcare AI on data advantage, regulatory proximity, and conversion of bookings to cash. While the company has not disclosed a formal long-term margin target, the CFO’s emphasis on prudent capital allocation to high-value disease areas and strategic customers points to compounding unit economics rather than top-line-at-all-costs. That shift typically reduces volatility in Hong Kong small and mid-cap tech names.
China’s industrial playbook is increasingly synchronized. The same manufacturing discipline that enabled cost-down, scale-up wins in EVs and energy storage is now being applied to clinical-grade AI. The export opportunity is not limited to software licenses. It extends to end-to-end solutions: data governance frameworks, standardized disease models, and implementation toolkits for emerging-market hospital groups and public health authorities. European industry is paying attention, with strategy reviews flagging systemic pressure from China’s lead in AI, clean energy, and advanced manufacturing. In healthcare, that pressure will manifest in competitive tenders for digital hospital infrastructure and real-world evidence networks. A well-governed, medically literate AI stack like YiduCore is a competitive export product, especially in regions trying to leapfrog legacy IT with AI-native architectures.
Three trackers will determine the next phase. First, the pace at which hospital solutions transition from projects to catalog products with clear SKUs, support models, and margin visibility. Second, the cadence of provincial and national platform wins that lock in multi-year, recurring budgets. Third, conversion of life sciences new orders into higher-margin analytics and evidence-generation revenue for pharma clients. Investors should also monitor how Yidu leverages its 21 disease-specific datasets into specialist modules for oncology, cardiovascular, and chronic disease management. Management’s commitment to focus on high-value disease areas suggests a roadmap of targeted, high-ARPU releases rather than broad but shallow feature sets.
Yidu Tech’s FY2026 print reads like the moment a decade of groundwork snaps into place. The company beat guidance, scaled EBITDA, expanded margins, and flipped H2 operating cash flow positive, all while deepening its role in national AI pilots and provincial platforms. The CEO’s message of capability-to-commercial shift and the CFO’s insistence on no one-offs align with what global investors want from China’s AI names: platform economics, policy alignment, and cash credibility. In a year when China is deploying humanoid robots, locking in gigawatt-hours of storage, and extending its EV lead, healthcare AI is earning its seat at the front of the growth cycle. Yidu’s data moat and product trajectory make 02158.HK a live case study in how China converts innovation scale into shareholder returns and global influence.
